← Leaderboards

Heinz Josef Lenz

University Of Southern California

Google Scholar ↗PubMed ↗ORCID ↗

$20,123,312

Attributed

$36,844,933

Total exposure

36

Grants

22

Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $6.5M · FY2005–25

$10M$7.5M$5M$2.5M$0

'05

'06

'07

'08

'09

'10

'11

'12

'13

'14

'15

'16

'17

'18

'19

'20

'21

'22

'23

'24

'25

Funding mix

By agency

NIH$53,479,147 · 37

By mechanism

U2C$19,933,602 · 4

UM1$17,699,866 · 1

U10$6,377,406 · 3

R01$4,745,110 · 3

UG1$2,937,479 · 1

M01$1,075,517 · 21

Top collaborators

Most similar at University Of Southern California

Same institution · by research overlap

Daniel S Levy$2,632,071
Michael Kahn$2,429,658
David Ian Quinn$4,779,068
Derek Raghavan$1,863,220
Caryn Lerman$95,133,528

Others in their field

Top investigators on “Clinical Research”

David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
Sonia M Thomas · Research Triangle Institute$700,865,642
Jeffrey P Krischer · University Of South Florida$611,867,176
Barton F Haynes · Duke University$538,862,577

Research focus

Clinical ResearchMalignant NeoplasmsResearch PersonnelClinical TrialsMolecularResourcesFundingTumorHuman SubjectNeoplasm /Cancer ChemotherapySafetyDrug KineticsToxic EffectPharmacokineticsGrantPharmacodynamicsResponseDesignLeadershipLeadMemberCaliforniaLaboratoriesAward

Grant awards (103)

USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization Studies$3,712,500

U2C · FY2025 · CA · contact PI

Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN$1,903,401

UM1 · FY2025 · CA

Administrative Core$506,733

U2C · FY2025 · CA · contact PI

NCTN - Network Lead Academic Participating Site: USC$390,493

UG1 · FY2025 · CA · contact PI

USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization Studies$3,810,841

U2C · FY2024 · CA · contact PI

Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN$1,293,587

UM1 · FY2024 · CA

Participant Engagement Unit$806,962

U2C · FY2024 · CA · contact PI

NCTN - Network Lead Academic Participating Site: USC$390,494

UG1 · FY2024 · CA · contact PI

Translational and Clinical Sciences$109,954

P30 · FY2024 · CA · contact PI

Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN$1,594,203

UM1 · FY2023 · CA

USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization Studies$1,386,086

U2C · FY2023 · CA · contact PI

NCTN - Network Lead Academic Participating Site: USC$381,932

UG1 · FY2023 · CA · contact PI

Participant Engagement Unit$293,510

U2C · FY2023 · CA · contact PI

Translational and Clinical Sciences$122,171

P30 · FY2023 · CA · contact PI

USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization Studies$4,012,287

U2C · FY2022 · CA

Participant Engagement Unit$849,617

U2C · FY2022 · CA · contact PI

NCTN - Network Lead Academic Participating Site: USC$430,768

UG1 · FY2022 · CA · contact PI

USC PE-GCS: Optimizing Engagement of Hispanic Colorectal Cancer Patients in Cancer Genomic Characterization Studies$3,712,500

U2C · FY2021 · CA

Participant Engagement Unit$842,566

U2C · FY2021 · CA · contact PI

NCTN - Network Lead Academic Participating Site: USC$409,376

UG1 · FY2021 · CA · contact PI

Phase 1 and 2 Molecular and Clinical Pharmacodynamic Trials ETCTN$5,651,467

UM1 · FY2020 · CA

NCTN - Network Lead Academic Participating Site: USC$464,856

UG1 · FY2020 · CA · contact PI

Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN$1,582,668

UM1 · FY2019 · CA

NCTN - Network Lead Academic Participating Site: USC$469,560

UG1 · FY2019 · CA · contact PI

Gastrointestinal Cancers Research Program (Project-006)$70,376

P30 · FY2019 · CA · contact PI

Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN$2,015,876

UM1 · FY2018 · CA

NCI NCTN- Network Lead Academic Participating Site: USC$523,827

U10 · FY2018 · CA · contact PI

NCI NCTN- Network Lead Academic Participating Site: USC$596,003

U10 · FY2017 · CA · contact PI

Efficacy of Novel Wnt Modulator in Colon Cancer$441,769

R01 · FY2017 · CA · contact PI

Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN$1,045,842

UM1 · FY2016 · CA

Phase I Molecular and Clinical Pharmacodynamic Trials ETCTN$871,140

UM1 · FY2016 · CA

NCI NCTN- Network Lead Academic Participating Site: USC$627,370

U10 · FY2016 · CA · contact PI

Efficacy of Novel Wnt Modulator in Colon Cancer$482,134

R01 · FY2016 · CA · contact PI

Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN$841,026

UM1 · FY2015 · CA

NCI NCTN- Network Lead Academic Participating Site: USC$646,885

U10 · FY2015 · CA · contact PI

Efficacy of Novel Wnt Modulator in Colon Cancer$488,640

R01 · FY2015 · CA · contact PI

Phase I Molecular and Clinical Pharmacodynamic Trials ET-CTN$900,656

UM1 · FY2014 · CA

NCI NCTN- Network Lead Academic Participating Site: USC$629,001

U10 · FY2014 · CA · contact PI

Efficacy of Novel Wnt Modulator in Colon Cancer$515,533

R01 · FY2014 · CA · contact PI

Efficacy of Novel Wnt Modulator in Colon Cancer$356,172

R01 · FY2013 · CA · contact PI

Southwest Oncology Group$337,210

U10 · FY2013 · CA · contact PI

Southwest Oncology Group$337,375

U10 · FY2012 · CA · contact PI

Southwest Oncology Group$337,375

U10 · FY2011 · CA · contact PI

Southwest Oncology Group$337,376

U10 · FY2010 · CA · contact PI

Southwest Oncology Group$262,855

U10 · FY2009 · CA · contact PI

PHI-55 A PAHSE 1 STUDY OF HALINCHRONDRIN B ANALOG (E7389) IN COMBINATION W$26,669

M01 · FY2009 · RR · contact PI

PHI-50 PHASE I AND PHARMACOKINETICS STUDY OF VIRINOSTAT FOR SOLID TUMORS AND$15,072

M01 · FY2009 · RR · contact PI

A PHASE I AND PHARMACOKINETIC STUDY OF ORAL 3-AMINOPYRIDINE-2- CARBOXALDEHYDE$13,914

M01 · FY2009 · RR · contact PI

A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS (CCI779)$10,435

M01 · FY2009 · RR · contact PI

0C-07-9, PH1-60 A PHASE 1 AND PHARMACOKINETIC SINGLE AGENT STUDY OF PAZOPANIB$9,277

M01 · FY2009 · RR · contact PI

PH1-61 A PHASE 1 STUDY OF ABT-888 IN COMBINATION WITH CARBOPLATIN AND PACLITA$1,158

M01 · FY2009 · RR · contact PI

Southwest Oncology Group$256,651

U10 · FY2008 · CA · contact PI

A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS (CCI779)$50,473

M01 · FY2008 · RR · contact PI

Southwest Oncology Group$252,261

U10 · FY2007 · CA · contact PI

Rectal Cancer: Molecular Markers of Outcome and Toxicity$228,397

R01 · FY2007 · CA · contact PI

A PHASE I PHARMACOKINETIC AND PHARMACODYNAMIC STUDY OF TEMSIROLIMUS (CCI779)$40,703

M01 · FY2007 · RR · contact PI

Southwest Oncology Group$20,000

U10 · FY2007 · CA · contact PI

Rectal Cancer: Molecular Markers of Outcome and Toxicity$353,534

R01 · FY2006 · CA · contact PI

Southwest Oncology Group$258,128

U10 · FY2006 · CA · contact PI

A PHASE I PHARMACOKINETIC STUDY OF EPOTHILONE B ANALOGUE BMS-247550 (NSC-170428D$33,748

M01 · FY2006 · RR · contact PI

PH-I-45: 0C-04-1, PHASE I TRIAL OF ARSENIC TRIOXIDE IN COMBINATION WITH$4,354

M01 · FY2006 · RR · contact PI

A PHASE 1 STUDY OF PS-341 IN COMBINATION WITH 5-FU/LV IN SOLID TUMORS$2,178

M01 · FY2006 · RR · contact PI

Rectal Cancer: Molecular Markers of Outcome and Toxicity$394,967

R01 · FY2005 · CA

Southwest Oncology Group$317,259

U10 · FY2005 · CA

PHASE I TRIAL OF E7389 (HALICHONDRIN B ANALOG) (IND #54,223) IN PATIENTS$40,285

M01 · FY2005 · RR

A PHASE I PHARMACOKINETIC STUDY OF EPOTHILONE B ANALOGUE BMS-247550 (NSC-170428D$33,056

M01 · FY2005 · RR

PHASE I PHARMACOKINETIC STUDY OF STI571 IN PATIENTS WITH ADVANCED MALIGNANCIES$8,265

M01 · FY2005 · RR

A PHASE I PHARMACOKINETIC STUDY OF PS341 IN PATIENTS WITH ADVANCED MALIGNANCIES$7,230

M01 · FY2005 · RR

A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III STUDY$4,131

M01 · FY2005 · RR

PH I/II ESCALATING, SINGLE DOSE, COHORT TRIAL TO DETERMINE THE SAFETY,$1,032

M01 · FY2005 · RR

A PHASE 1 STUDY OF PS-341 IN COMBINATION WITH 5-FU/LV IN SOLID TUMORS$1,032

M01 · FY2005 · RR

Rectal Cancer: Molecular Markers of Outcome and Toxicity$465,546

R01 · FY2004 · CA

Southwest Oncology Group$236,651

U10 · FY2004 · CA

DETERMINANTS OF CANCER RISK AND OUTCOME IN GI ONCOLOGY$88,051

K24 · FY2004 · CA

Phase I Pharmacokinetic study of STI571 in Patients$36,371

M01 · FY2004 · RR

A Phase 1 Study of PS-341 in Combination with 5-FU/LV$6,419

M01 · FY2004 · RR

DETERMINANTS OF CANCER RISK AND OUTCOME IN GI ONCOLOGY$84,664

K24 · FY2003 · CA

PHARMACOLOGY OF ANTICANCER DRUGS IN ADVANCED AGE$9,009

U10 · FY2003 · CA

PHARMACOLOGY OF ANTICANCER DRUGS IN ADVANCED AGE$392,170

U10 · FY2002 · CA

DETERMINANTS OF CLINICAL OUTCOME/TOXICITY IN HISPANICS$348,860

R01 · FY2002 · CA

DETERMINANTS OF CANCER RISK AND OUTCOME IN GI ONCOLOGY$81,408

K24 · FY2002 · CA

POLYMORPHISM IN PATIENTS W/ COLORECTAL CANCER TREATED W/ CPT 11$0

M01 · FY2002 · RR

96 HR INFUSION OF ICRF 187 FOLLOWED BY 72 HR INFUSION OF TOPOTECAN$0

M01 · FY2002 · RR

BRYOSTATIN IN COMBINATION W/ CISPLATIN IN CANCER PATIENTS$0

M01 · FY2002 · RR

PHASE I STUDY OF TAXOTERE IN PATIENTS WITH ADVANCED MALIGNANCIES$0

M01 · FY2002 · RR

DETERMINANTS OF CLINICAL OUTCOME/TOXICITY IN HISPANICS$338,699

R01 · FY2001 · CA

PHASE I STUDY OF TAXOTERE IN PATIENTS WITH ADVANCED MALIGNANCIES$155,764

M01 · FY2001 · RR

POLYMORPHISM IN PATIENTS W/ COLORECTAL CANCER TREATED W/ CPT 11$155,764

M01 · FY2001 · RR

96 HR INFUSION OF ICRF 187 FOLLOWED BY 72 HR INFUSION OF TOPOTECAN$155,764

M01 · FY2001 · RR

BRYOSTATIN IN COMBINATION W/ CISPLATIN IN CANCER PATIENTS$155,764

M01 · FY2001 · RR

DETERMINANTS OF CANCER RISK AND OUTCOME IN GI ONCOLOGY$78,277

K24 · FY2001 · CA

96 HR INFUSION OF ICRF 187 FOLLOWED BY 72 HR INFUSION OF TOPOTECAN$0

M01 · FY2001 · RR

POLYMORPHISM IN PATIENTS W/ COLORECTAL CANCER TREATED W/ CPT 11$0

M01 · FY2001 · RR

BRYOSTATIN IN COMBINATION W/ CISPLATIN IN CANCER PATIENTS$0

M01 · FY2001 · RR

PHASE I STUDY OF TAXOTERE IN PATIENTS WITH ADVANCED MALIGNANCIES$0

M01 · FY2001 · RR

DETERMINANTS OF CLINICAL OUTCOME/TOXICITY IN HISPANICS$330,859

R01 · FY2000 · CA

DETERMINANTS OF CANCER RISK AND OUTCOME IN GI ONCOLOGY$75,266

K24 · FY2000 · CA

96 HR INFUSION OF ICRF 187 FOLLOWED BY 72 HR INFUSION OF TOPOTECAN$35,553

M01 · FY2000 · RR

PHASE I STUDY OF TAXOTERE IN PATIENTS WITH ADVANCED MALIGNANCIES$35,553

M01 · FY2000 · RR

POLYMORPHISM IN PATIENTS W/ COLORECTAL CANCER TREATED W/ CPT 11$35,553

M01 · FY2000 · RR

96 HR INFUSION OF ICRF 187 FOLLOWED BY 72 HR INFUSION OF TOPOTECAN$0

M01 · FY2000 · RR

PHASE I STUDY OF TAXOTERE IN PATIENTS WITH ADVANCED MALIGNANCIES$0

M01 · FY2000 · RR

POLYMORPHISM IN PATIENTS W/ COLORECTAL CANCER TREATED W/ CPT 11$0

M01 · FY2000 · RR